Inflammation

PALO ALTO, Calif. and NEW YORK — September 23, 2026 Evommune, Inc. announced that Phase 2a data for EVO301...

Toronto, Ontario, Canada, September 23, 2026 Cardiol Therapeutics has announced that its pivotal Phase III MAVERIC clinical trial evaluating...

Thousand Oaks, California, U.S., September 22, 2026 Amgen has announced positive topline results from the pivotal Phase 3 OASIZ...

DENVER, Colo. — September 22, 2026 Palisade Bio announced that the U.S. Food and Drug Administration has cleared the...

Washington, D.C., September 20, 2026 The Heart Failure Society of America (HFSA) has announced the late-breaking clinical research program...

New York, United States, September 20, 2026 Accro Bioscience has announced that the first patient has been dosed in...

SOUTH SAN FRANCISCO, Calif. — September 17, 2026 Dualitas Therapeutics announced a research collaboration and license agreement with Roche...

Valencia, California, USA, September 16, 2026 SetPoint Medical announced that Oregon Health & Science University (OHSU) has become the...

Burlington, Massachusetts, U.S., September 10, 2026 Consano Bio, Inc. has announced the publication of peer-reviewed nonclinical research evaluating C-1101,...

EDINBURGH and LONDON, UK — September 11, 2026 Resolution Therapeutics Limited announced that the final patient has been treated...